Omeros seeks orphan-drug status for rare disease drug

04/22/2013 | Pharmaceutical Business Review Online

Omeros submitted an application to the FDA seeking orphan-drug designation for OMS721, an investigational drug for atypical hemolytic uremic syndrome. The drug, which targets the lectin pathway of the complement system, is formulated for self-administration through subcutaneous injection. The firm plans to apply for a similar designation in Europe and to initiate clinical studies in the summer.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR